<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8208">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01876004</url>
  </required_header>
  <id_info>
    <org_study_id>CEP UNIFESP 0772/11</org_study_id>
    <nct_id>NCT01876004</nct_id>
  </id_info>
  <brief_title>Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy</brief_title>
  <official_title>Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To evaluate if, when considering expectant management in tubal ectopic pregnancy
      if the complementary use of Methotrexate could provide better results. We evaluate the
      success of treatment and the time required for titers of β-hCG to become negative. Methods:
      A double-blind randomized study, held at the Department of Obstetrics UNIFESP. The patients
      will be divided into two groups: in one patients will be administered a single intramuscular
      dose of 50 mg/m2 of Methotrexate and in the other patients will be prescribed Placebo
      intramuscularly. The monitoring will be done by measurement of β-hCG in the 4th and 7th day.
      When the decline of beta-hCG titers was &gt; 15% in this interval, the patient was followed
      with weekly dosing of β-hCG until the titers become negative. The criterion of success is
      when the β-hCG was negative. The treatment failure occurs when surgery was necessary.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>success of treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>β-hCG negative (&lt;5 mIU / mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time required for titers of β-hCG to become negative</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After medication, monitoring will be done by measurement of β-hCG in the 4th and 7th day. If there ia a decrease &gt; 15% in this range (4th and 7th), patient will be followed with weekly dosing of β-hCG until negative titers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood tests before treatment with Methotrexate and Placebo</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Average value for tests: complete blood count, liver and renal function in the groups Methotrexate and Placebo before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood tests after treatment with Methotrexate and Placebo</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Average value for tests: complete blood count, liver and renal function in the groups Methotrexate and Placebo before and after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Ectopic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prescribed Placebo intramuscularly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>50 mg/m2, IM (intramuscularly), single dose</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prescribed Placebo IM (intramuscularly), single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodynamic stability

          -  Initial β-hCG &lt;2000 mIU / mL

          -  Titers of β-hCG in decline in 48 hours before treatment

          -  Adnexal mass &lt;5.0 cm

          -  Desire for future pregnancy

        Exclusion Criteria:

          -  Alive embryo

          -  Ectopic pregnancy other than in tubal location

          -  Pregnancy of unknown location
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Elito Junior</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luiz Camano</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 10, 2013</lastchanged_date>
  <firstreceived_date>June 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Priscila Matthiesen e Silva</investigator_full_name>
    <investigator_title>Obstetrics and Gynecologist</investigator_title>
  </responsible_party>
  <keyword>ectopic pregnancy</keyword>
  <keyword>methotrexate</keyword>
  <keyword>human chorionic gonadotropin beta subunit</keyword>
  <keyword>expectant management</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pregnancy, Ectopic</mesh_term>
    <mesh_term>Pregnancy, Tubal</mesh_term>
    <mesh_term>Cardiac Complexes, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
